Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study.

10 May 2018

New case study shows CAR T therapy as viable option for AML patients

Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune cells to fight cancer.

9 May 2018

New findings point to potential therapeutic avenues for leukemia

Scientists have known for decades that the Hox family of transcription factors are key regulators in the formation of blood cells and the development of leukemia.

9 May 2018

Moving beyond traditional 'magic bullet' approach for discovering new drugs

It's time to move beyond the traditional 'magic bullet' approach for discovering new drugs and start leveraging the full complexity of Mother Nature, say Vanderbilt Professor of Chemistry Brian Bachmann and Assistant Professor of Cell and Developmental Biology Jonathan Irish.

3 May 2018

Researchers identify novel pathway in development of AML with poor prognosis

Acute myeloid leukemia is a cancer of the blood and bone marrow that comprises 1% of all new cancer cases and almost 2% of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20%.

24 Apr 2018

Experimental peptide drug shows promise against acute myeloid leukemia

In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide drug shows promise against the often-lethal cancer acute myeloid leukemia and describe how the drug works at the molecular level.

11 Apr 2018

New class of drug holds potential to help patients with treatment-resistant cancers

Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.

10 Apr 2018

Researchers probe RNA epigenetics and chromatin structures to predict drug resistance in leukemia

Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

23 Mar 2018

Researchers discover key inner control mechanism of cell's 'smart glue'

Researchers at St. Jude Children's Research Hospital have discovered that a protein critical to a process called liquid-liquid phase separation within the cell undergoes internal changes in conformation that are key to its function.

26 Feb 2018

New NK cell-based immunotherapy effective against several types of leukemia

Researchers at Karolinska Institutet in Sweden have explored NK cell-based immunotherapy on patients with treatment-resistant leukemia. The study, which is published in the scientific journal Clinical Cancer Research, shows that the new therapy is effective against several types of leukemia.

15 Feb 2018

Researchers solve crystal structure for enzyme that plays key role in DNA methylation

A research team led by a biochemist at the University of California, Riverside has solved the crystal structure for an enzyme that plays a key role in DNA methylation, the process by which methyl groups are added to the DNA molecule.

7 Feb 2018

Modular gene enhancers may be suitable target in treatment of blood cancer

Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer.

18 Jan 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

Leukemia patients currently ineligible for targeted therapy may benefit from new drugs

Patients with an aggressive form of leukemia, currently ineligible for any type of targeted therapy, may in fact benefit from some of these new drugs, according to new research by Queen Mary University of London.

9 Jan 2018

Study reveals novel molecular targets to improve chemotherapy’s efficiency against leukemia

Researchers from Instituto de Medicina Molecular João Lobo Antunes have found a mechanism through which certain types of leukemia resist chemotherapy, thus revealing novel molecular targets that may be used to improve the efficiency of this type of treatment.

12 Dec 2017

Study: Combination targeted therapy has high response rates in AML patients

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2017

Pairing immunotherapy drug with chemotherapy proves beneficial for relapsed acute myeloid leukemia

University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.

11 Dec 2017

Clinical study uses genetic testing to match AML patients with new therapies

A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

6 Dec 2017

UC San Diego researchers receive nearly $8 million grant for new stem cell-based AML treatments

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML.

4 Dec 2017